Are prostate cancer bone lesions considered 'cold' on imaging studies, such as bone scans, in patients with a history of prostate cancer?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 25, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Are Prostate Cancer Bone Lesions Considered "Cold"?

No, prostate cancer bone metastases typically appear as "hot" lesions on bone scintigraphy, not "cold" lesions, because prostate cancer characteristically produces osteoblastic or mixed osteoblastic-osteolytic bone metastases that generate increased radiotracer uptake. 1

Why Prostate Cancer Lesions Are Usually "Hot"

  • Prostate cancer bone metastases are predominantly osteoblastic or mixed in nature, triggering reactive new bone formation that produces focal increases in tracer uptake on technetium-99m bone scans 1, 2

  • Bone scintigraphy detects the osteoblastic response to tumor, not the tumor itself directly—the radiotracer (99mTc-MDP) is taken up by active osteoblasts at sites of increased bone formation 1, 2

  • Radionuclide bone scans are highly sensitive to osteoblastic and mixed osteolytic-osteoblastic lesions such as those from prostate and breast cancer, making them appear as areas of increased radiotracer uptake ("hot spots") 1, 2

When "Cold" Lesions Occur (Rare in Prostate Cancer)

  • "Cold" lesions (photon-deficient areas) on bone scans are predominantly seen with purely osteolytic metastases from cancers like kidney, thyroid, and multiple myeloma—not typically prostate cancer 1, 3, 4

  • Bone scans are relatively insensitive for purely osteolytic lesions, with sensitivity as low as 62% in predominantly lytic disease, because these lesions lack the osteoblastic response needed for radiotracer uptake 1, 2

  • Historical case series show "cold" lesions occurred in only 1.8% of abnormal bone scans across various malignancies, and when present, they were more common in tubular and denser bones 4, 5

Clinical Implications for Prostate Cancer Imaging

  • The characteristic "hot" appearance of prostate cancer bone metastases makes conventional bone scintigraphy a reasonable screening tool for higher-risk patients (PSA >20 ng/mL or Gleason score ≥8) 1

  • However, bone scans have significant limitations: they image the body's response to tumor rather than the tumor itself, leading to the "flare phenomenon" where healing lesions can mimic progression 1, 2

  • More advanced imaging modalities are superior: 18F-sodium fluoride PET detects lesions before conventional bone scans become positive, and FDG-PET directly assesses metabolic activity of metastatic tissue 1, 2

Key Pitfall to Avoid

Do not assume a negative bone scan excludes bone metastases in prostate cancer—while prostate lesions are typically "hot," bone scans can miss early marrow-based metastases before they provoke sufficient osteoblastic response, and MRI has superior sensitivity (82-100%) for detecting these early lesions 1, 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Bone Scan (Radionuclide Bone Scintigraphy)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Bony Lytic Lesions

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

"Cold" lesions on bone imaging.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1975

Research

["Cold lesions" in bone scintigraphy (author's transl)].

RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin, 1979

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.